May 2025 | AIChE

You are here

May 2025

2025-26 Election, Slate Bios

2025-2026 AIChE Chicago Elected Officers Chair: Lance Baird Lance Baird is the owner of Lance Baird, LLC specializing in Renewable Energy and is a co-founder of RenewAgility, LLC. Lance retired from Honeywell UOP after 37 years of service, including 15 years on worldwide technical service assignments and 22 years in various roles in technology development. He holds 21 patents with 16 applications pending and is a 6-sigma black belt. Lance graduated from Washington State University with a BS in Chemical Engineering. He is currently serving AIChE Chicago as the Chair-elect and previously served...

Joleen Masschelein

Joleen Masschelein leads the Laboratory for Biomolecular Discovery and Engineering at the VIB-KU Leuven Center for Microbiology in Belgium. She studied Bioscience Engineering at KU Leuven, where she earned her PhD in 2015, focusing on the discovery and characterization of novel antibiotics. She was subsequently awarded a Marie-Sklodowska Curie Individual Fellowship from the European Commission to continue her research at the Department of Chemistry at the University of Warwick. In 2017, she moved to the Laboratory for Medicinal Chemistry at KU Leuven as a...Read more

All types of knowledge, ultimately mean self knowledge.

Bruce Lee, martial artist, actor, director, philosopher May is Asian American, Native Hawaiian, and Pacific Islander Heritage

Use criticism as a catalyst for change

Being criticized can often cause emotional pain, but executive coach Steve Keating recommends treating such feedback as an op - More -

Center for Chemical Process Safety marks 40 years

The Center for Chemical Process Safety (CCPS), a technical directorate of AIChE, commemorated 40 years of leadership and cont - More -

Who was the first Asian American President of AIChE?

The correct answer will appear in next week's issue of AIChE SmartBrief. - More -

Pharma exports surge amid specter of tariffs

Pharmaceutical exports from Europe to the US have surged as companies stockpile ahead of potential tariffs threatened by Pres - More -

Enhertu data could support use in early breast cancer

A phase 3 trial of AstraZeneca and Daiichi Sankyo's Enhertu showed the drug improved pathological complete response rates as - More -

Pages